Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

NCT03240939 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: Dutasteride 0.5 mg
DRUG: Tadalafil 5 mg
DRUG: YY-201

Sponsor

Yuyu Pharma, Inc.